Thompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Thompson Siegel & Walmsley LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 513,632 shares of the company's stock, valued at approximately $5,927,000. Thompson Siegel & Walmsley LLC owned 0.07% of Roivant Sciences at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in ROIV. Gladius Capital Management LP purchased a new stake in shares of Roivant Sciences in the third quarter worth about $35,000. nVerses Capital LLC acquired a new stake in shares of Roivant Sciences during the 2nd quarter valued at about $34,000. US Bancorp DE grew its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences in the 2nd quarter valued at about $36,000. Finally, Quarry LP acquired a new position in Roivant Sciences in the 2nd quarter worth about $53,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ROIV shares. Bank of America increased their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.93.

Roivant Sciences Stock Up 6.0 %

Shares of Roivant Sciences stock traded up $0.71 during trading hours on Friday, reaching $12.53. 11,220,827 shares of the company's stock were exchanged, compared to its average volume of 5,857,028. The business has a fifty day moving average of $11.68 and a two-hundred day moving average of $11.32. The company has a market capitalization of $9.27 billion, a P/E ratio of 2.10 and a beta of 1.24. Roivant Sciences Ltd. has a 1 year low of $8.61 and a 1 year high of $13.06.

Insider Activity at Roivant Sciences

In other news, CAO Rakhi Kumar sold 250,000 shares of the business's stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the transaction, the chief accounting officer now owns 209,322 shares of the company's stock, valued at approximately $2,488,838.58. The trade was a 54.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares of the company's stock, valued at approximately $7,193,525.50. The trade was a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,677,309 shares of company stock valued at $43,283,184. Corporate insiders own 7.90% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.